Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Tarsus Pharmaceuticals
(NASDAQ:TARS)
Intraday
$34.57
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$34.57
0
[0.00%]
Last update: 4:00PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Tarsus Pharmaceuticals Stock (NASDAQ:TARS)
Tarsus Pharmaceuticals Stock (NASDAQ: TARS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, March 01, 2024
Tarsus Prices $100M Public Offering Of 2,812,500 Common Shares At $32/Share
Benzinga Newsdesk
-
Mar 1, 2024, 1:26AM
Thursday, February 29, 2024
Tarsus Pharmaceuticals Reveals Proposed $100M Public Offering
Benzinga Newsdesk
-
Feb 29, 2024, 4:47PM
A Glimpse Into The Expert Outlook On Tarsus Pharmaceuticals Through 4 Analysts
Benzinga Insights
-
Feb 29, 2024, 7:00AM
Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $30
Benzinga Newsdesk
-
Feb 29, 2024, 6:08AM
Wednesday, February 28, 2024
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $57
Benzinga Newsdesk
-
Feb 28, 2024, 2:04PM
Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk
-
Feb 28, 2024, 11:15AM
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor
-
Feb 28, 2024, 8:07AM
Oppenheimer Reiterates Outperform on Tarsus Pharmaceuticals, Raises Price Target to $59
Benzinga Newsdesk
-
Feb 28, 2024, 7:48AM
Tuesday, February 27, 2024
Tarsus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.
Benzinga Newsdesk
-
Feb 27, 2024, 12:35PM
Tarsus Pharmaceuticals Q4 EPS $(1.31) Beats $(1.36) Estimate, Sales $13.08M Beat $5.66M Estimate
Benzinga Newsdesk
-
Feb 27, 2024, 12:27PM
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Monday, February 26, 2024
Tarsus Pharmaceuticals's Earnings: A Preview
Benzinga Insights
-
Feb 26, 2024, 2:01PM
Thursday, February 22, 2024
Tarsus Announces Topline Results From Phase 2a Carpo Trial Evaluating TP-05 For Prevention Of Lyme Disease
Benzinga Newsdesk
-
Feb 22, 2024, 8:07AM
Monday, January 29, 2024
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
Avi Kapoor
-
Jan 29, 2024, 10:31AM
Monday, December 11, 2023
Tarsus Announces Topline Results From Ersa Phase 2a Clinical Trial Of TP-03 For Meibomian Gland Disease In Patients With Demodex Mites; TP-03 Demonstrated Statistically Significant And Clinical Meaningful Improvements Compared To Baseline In Two Measures
Benzinga Newsdesk
-
Dec 11, 2023, 8:06AM
Monday, November 20, 2023
Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals with Neutral Rating, Announces Price Target of $19
Benzinga Newsdesk
-
Nov 20, 2023, 4:43AM
Friday, November 10, 2023
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
Nov 10, 2023, 1:34PM
Tarsus Pharmaceuticals shares are trading higher following Q3 results.
Benzinga Newsdesk
-
Nov 10, 2023, 12:11PM
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Benzinga Insights
-
Nov 10, 2023, 12:00PM
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
Lisa Levin
-
Nov 10, 2023, 11:51AM
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk
-
Nov 10, 2023, 7:44AM
Thursday, November 09, 2023
Tarsus Pharmaceuticals Q3 EPS $(1.28) Vs $(0.84) Last Year, Sales $1.87M Beat $399.8K Estimate
Benzinga Newsdesk
-
Nov 9, 2023, 4:56PM
Recap: Tarsus Pharmaceuticals Q3 Earnings
Benzinga Insights
-
Nov 9, 2023, 4:30PM
Earnings Scheduled For November 9, 2023
Benzinga Insights
-
Nov 9, 2023, 6:52AM
Wednesday, November 08, 2023
Earnings Preview: Tarsus Pharmaceuticals
Benzinga Insights
-
Nov 8, 2023, 11:01AM
Monday, September 11, 2023
Expert Ratings for Tarsus Pharmaceuticals
Benzinga Insights
-
Sep 11, 2023, 10:00AM
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49
Benzinga Newsdesk
-
Sep 11, 2023, 9:52AM
Thursday, August 24, 2023
Tarsus Pharmaceuticals, Inc. Announces That XDEMVY 0.25% Is Now Available At Pharmacies Nationwide For Prescription. The U.S. FDA Approved Drug On July 24, 2023, For The Treatment Of Demodex Blepharitis
Happy Mohamed
-
Aug 24, 2023, 9:11AM
Monday, August 14, 2023
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
Benzinga Insights
-
Aug 14, 2023, 2:00PM
Guggenheim Reiterates Buy on Tarsus Pharmaceuticals, Maintains $46 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 8:38AM
Friday, August 11, 2023
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $42
Benzinga Newsdesk
-
Aug 11, 2023, 6:26AM
Thursday, August 10, 2023
Tarsus Pharmaceuticals Q2 EPS $(1.17) Down From $(0.24) YoY
Benzinga Newsdesk
-
Aug 10, 2023, 5:15PM
Wednesday, August 02, 2023
Tarsus Pharmaceuticals Announces Pricing Of $100M Underwritten Public Offering Of 5,714,285 Shares Of Common Stock At $17.50/Share
Benzinga Newsdesk
-
Aug 2, 2023, 2:12AM
Tuesday, August 01, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Aug 1, 2023, 1:31PM
Late Monday, Tarsus Pharmaceuticals Announced The Commencement Of An Underwritten Public Offering Of $100M, Price Terms Were Not Disclosed
Benzinga Newsdesk
-
Aug 1, 2023, 8:06AM
Monday, July 31, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jul 31, 2023, 5:31PM
Wednesday, July 26, 2023
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Benzinga Insights
-
Jul 26, 2023, 1:00PM
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk
-
Jul 26, 2023, 6:10AM
Tuesday, July 25, 2023
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
Vandana Singh
-
Jul 25, 2023, 3:39PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Jul 25, 2023, 1:31PM
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Jul 25, 2023, 1:11PM
The FDA Has Approved Tarsus Pharmaceuticals' Xdemvy (Lotilaner Ophthalmic Solution, Formerly TP-03) 0.25% For Demodex Blepharitis; Xdemvy Expected To Be Available By Prescription By The End Of August 2023
Benzinga Newsdesk
-
Jul 25, 2023, 7:04AM
Thursday, July 20, 2023
Why Infosys Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
Jul 20, 2023, 1:26PM
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday
Lisa Levin
-
Jul 20, 2023, 10:02AM
Tuesday, July 18, 2023
Benzinga's Top Ratings Upgrades, Downgrades For July 18, 2023
Benzinga Insights
-
Jul 18, 2023, 11:00AM
William Blair Initiates Coverage On Tarsus Pharmaceuticals with Outperform Rating, Announces Price Target of $44
Benzinga Newsdesk
-
Jul 18, 2023, 9:36AM
Thursday, June 29, 2023
Short Interest Sector Focus: Healthcare Sector
Christopher Sappo
-
Jun 29, 2023, 12:56PM
Wednesday, June 28, 2023
Short Interest Sector Focus: Healthcare Sector
Christopher Sappo
-
Jun 28, 2023, 10:24AM
Monday, June 26, 2023
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $44
Benzinga Newsdesk
-
Jun 26, 2023, 6:10AM
Friday, June 16, 2023
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $42
Benzinga Newsdesk
-
Jun 16, 2023, 11:59AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch